8-KRegulation FDExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (Mar 5, 2014)

Filed March 5, 2014For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed a Form 8-K on March 4, 2014, to disclose important data presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. The filing includes presentation slides from a Phase 2a trial evaluating dupilumab, a human monoclonal antibody, for the treatment of atopic dermatitis. This data provides investors with an early look at the potential efficacy and safety of a key pipeline asset in a significant therapeutic area. The presentation details a 12-week, randomized, double-blind, placebo-controlled study of dupilumab monotherapy in adult patients with moderate-to-severe atopic dermatitis. The disclosure of this clinical trial data is a crucial event for investors, offering insights into the drug's performance and Regeneron's progress in developing treatments for inflammatory conditions. Investors will be keen to assess the clinical significance of the results and the potential for dupilumab to become a future revenue driver for the company.

Key Highlights

  • 1Disclosure of Phase 2a clinical trial data for dupilumab in atopic dermatitis patients.
  • 2Dupilumab is a human monoclonal antibody being evaluated for its therapeutic potential.
  • 3The trial was a 12-week, randomized, double-blind, placebo-controlled study.
  • 4Data was presented at the American Academy of Allergy, Asthma & Immunolgy (AAAAI) annual meeting.
  • 5The presentation slides are furnished as Exhibit 99.1 to the 8-K filing.
  • 6This data provides early insight into dupilumab's performance in a key therapeutic area.
  • 7The filing indicates Regeneron's ongoing commitment to advancing its drug pipeline.

Frequently Asked Questions

Dupilumab is a human monoclonal antibody. The data presented in this 8-K filing pertains to its evaluation in a Phase 2a clinical trial for the treatment of moderate-to-severe atopic dermatitis in adults.

The data was from a 12-week, randomized, double-blind, placebo-controlled study evaluating dupilumab as a monotherapy in patients with moderate-to-severe atopic dermatitis. The results were presented at the AAAAI annual meeting.

The presentation slides containing the data from the Phase 2a trial are furnished as Exhibit 99.1 to this Form 8-K filing and are incorporated by reference.

This filing is significant as it provides investors with early clinical data on dupilumab, a potentially important drug candidate for Regeneron. Positive results in this trial could signal future success and revenue potential for the company in the dermatology and immunology space.